Etoricoxib is a NSAID which inhibits synthesis of prostaglandins by inhibiting the activity of the enzyme cyclo-oxygenase-2(COX-2) which is administered orally as an analgesic and anti-inflammatory drug that is used for the treatment of osteoarthritis, rheumatoid arthritis and gouty arthritis. The objective of present study was to develop stability indicating method to generate reliable and accurate data for stability study. A simple, specific, accurate and stability-indicating UV- spectrophotometric method was developed for the estimation of etoricoxib, using an agilent model 60 spectrophotometer. The UV spectrum was scanned between 200 to 400 nm and 232 nm was selected as maximum wavelength for absorption and methanol was used as diluent. Linearity was established for etoricoxib in the range of 2-10 μg/ml with regression coefficient of 0.9912. The drug was subjected to acid, alkali and neutral hydrolysis, oxidation degradation conditions. The limits of detection (LOD) and quantification (LOQ) were calculated to be 0.096 and 0.292 μg ml, respectively. The method was found to be simple and less time consuming and cost effective. A simple, sensitive and appreciable stability indicating UV spectrophotometric method has been developed for etoricoxib in bulk. The method was fast and economical and it was also selective and sensitive for the desirable range.
Loading....